STOCK TITAN

Artivion Announces Release Date and Teleconference Call Details for Third Quarter 2023 Financial Results

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Artivion, Inc. to release third quarter 2023 financial results
Positive
  • Artivion, Inc. will release its third quarter 2023 financial results on November 2, 2023 after the market closes.
  • The Company will hold a teleconference call and live webcast at 4:30 p.m. ET on November 2, 2023 to discuss the results.
  • The earnings press release will contain financial and statistical information for the completed quarter and full year.
Negative
  • None.

ATLANTA, Oct. 19, 2023 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that third quarter 2023 financial results will be released on Thursday, November 2, 2023 after the market closes. On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m. ET to discuss the results, followed by a question and answer session hosted by Pat Mackin, Chairman, President and Chief Executive Officer of Artivion.

To listen to the live teleconference, please dial 862-298-0702 a few minutes prior to 4:30 p.m. ET. The teleconference replay will be available approximately one hour following the completion of the event and can be accessed by calling (toll free) 877-660-6853 or 201-612-7415. The conference number for the replay is 13741667. 

The live webcast and replay can be accessed on the Investors section of the Artivion website at www.artivion.com and by selecting Webcasts & Presentations. In addition, a copy of the earnings press release, which will contain financial and statistical information for the completed quarter and full year, can be accessed in the Investors section of the Artivion website.

About Artivion, Inc.
Headquartered in suburban Atlanta, Georgia, Artivion, Inc. is a medical device company focused on developing simple, elegant solutions that address cardiac and vascular surgeons' most difficult challenges in treating patients with aortic diseases. Artivion's four major groups of products include: aortic stent grafts, surgical sealants, On-X mechanical heart valves, and implantable cardiac and vascular human tissues. Artivion markets and sells products in more than 100 countries worldwide. For additional information about Artivion, visit our website, www.artivion.com.

Contacts:






























Artivion

D. Ashley Lee

Executive Vice President &

Chief Financial Officer
Phone: 770-419-3355














Gilmartin Group LLC

Brian Johnston / Lynn Lewis

Phone:  332-895-3222

investors@artivion.com 

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/artivion-announces-release-date-and-teleconference-call-details-for-third-quarter-2023-financial-results-301962557.html

SOURCE Artivion, Inc.

FAQ

When will Artivion, Inc. release its third quarter 2023 financial results?

Artivion, Inc. will release its third quarter 2023 financial results on Thursday, November 2, 2023 after the market closes.

What time will the teleconference call and live webcast be held?

The teleconference call and live webcast will be held at 4:30 p.m. ET on November 2, 2023.

Who will host the question and answer session?

Pat Mackin, Chairman, President and Chief Executive Officer of Artivion, will host the question and answer session.

Where can I access the live webcast and replay?

The live webcast and replay can be accessed on the Investors section of the Artivion website at www.artivion.com.

Artivion, Inc.

NYSE:AORT

AORT Rankings

AORT Latest News

AORT Stock Data

991.44M
34.32M
5.46%
86.87%
6.81%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
KENNESAW

About AORT

cryolife, headquartered in georgia, is a leader in the processing and distribution of human tissues for use in cardiac and vascular surgeries. cryolife using its proprietary synergraft® technology processes the cryovalve® sg pulmonary heart valve and cryopatch® sg pulmonary cardiac patch. cryolife’s bioglue® surgical adhesive is approved in the u.s. for use as an adjunct to sutures and staples to help control bleeding, ce marked in the european community, approved in canada and australia for use in soft tissue repair, and in japan for use in the repair of aortic dissections. cryolife’s cardiogenesis specializes in the treatment of severe angina using a laser console system and fiber-optic handpieces to perform a surgical procedure known as transmyocardial revascularization (tmr). cryolife markets the hero® graft, which provides vascular access for hemodialysis patients. cryolife distributes perclot®, an absorbable powdered hemostat, in international markets. cryolife’s biofoam® surgica